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Gallstones are responsible for one of the most common diseases in the Western world and
are commonly treated with cholecystectomy. We perform a meta-analysis of two genome-
wide association studies of gallstone disease in Iceland and the UK, totaling 27,174 cases and
736,838 controls, uncovering 21 novel gallstone-associated variants at 20 loci. Two distinct
low frequency missense variants in SLC10A2, encoding the apical sodium-dependent bile acid
transporter (ASBT), associate with an increased risk of gallstone disease (Pro290Ser: OR=
1.36 [1.25–1.49], P= 2.1 × 10–12, MAF= 1%; Val98Ile: OR= 1.15 [1.10–1.20], P= 1.8 × 10–10,
MAF= 4%). We demonstrate that lower bile acid transport by ASBT is accompanied by
greater risk of gallstone disease and highlight the role of the intestinal compartment of the
enterohepatic circulation of bile acids in gallstone disease susceptibility. Additionally, two low
frequency missense variants in SERPINA1 and HNF4A and 17 common variants represent
novel associations with gallstone disease.
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Gallstone disease (also known as cholelithiasis) is a com-mon condition affecting 10–15% of the population indeveloped countries1, and is often complicated by chole-
cystitis, pancreatitis and secondary infections2. Gallstones are
masses of solid material formed in the gallbladder, most com-
monly consisting of cholesterol2. Excess of cholesterol or a lack of
bile acids increase the likelihood of gallstone formation3. Treat-
ment by surgical removal of the gallbladder (cholecystectomy) is
one of the most common surgeries in the Western world, with
over 700,000 cholecystectomies performed annually in the United
States1.
A twin study estimated that genetic factors account for 25% [95%
CI: 9–40%] of the phenotypic variation of gallstone disease4.
Sequence variants at eight loci have been reported through genome-
wide association studies (GWAS) to affect the risk of gallstone
disease, including missense variants in ABCG5/ABCG85, encoding
ATP-binding cassette (ABC) transporters involved in the secretion
of cholesterol into bile6. We have reported two rare coding variants
in ABCB4 that greatly increase the risk of gallstone disease7. ABCB4
encodes the ABC transporter responsible for the secretion of leci-
thin into bile6. Other studies have reported sequence variants at
GCKR8, TM4SF48, SULT2A18, CYP7A18, UGT1A69, and TTC39B10
to associate with risk of gallstone disease.
To search for sequence variants affecting the risk of gallstone
disease, we perform a genome-wide association study (GWAS) of
27,174 cases and 736,838 controls from Iceland and the UK
biobank. Subsequently, we assess the association of gallstone
disease variants with acute pancreatitis, cholecystitis, fibrosis/
cirrhosis of liver, cholestasis of pregnancy, gallbladder cancer, six
liver biomarkers, and three cholesterol traits. We find four novel
low-frequency sequence variants in SLC10A2 (two distinct var-
iants), SERPINA1 and HNF4A that associate with gallstone dis-
ease. SLC10A2 encodes a protein that reabsorbs bile salts from the
terminal ileum as part of their enterohepatic circulation. Addi-
tionally, we describe 17 novel common variants that associate
with gallstone disease. Among those, two are in fucosyltransferase
genes, four associate with maturity onset diabetes of the young,
and six associate with lipid metabolism. We systematically assess
the effects of lipid associated variants with gallstone disease risk
and find inconsistent direction of effect. With the discovery of
gallstone-associated variants in SLC10A2, we highlight a role of
the intestinal compartment of the enterohepatic circulation of bile
acids in gallstone disease susceptibility.
Results
Overview. We performed a meta-analysis of gallstone disease,
combining GWAS results from Iceland (8757 cases and 346,688
controls) and the UK Biobank (18,417 cases and 390,150 con-
trols), for a total of 27,174 cases and 736,838 controls (Fig. 1,
Supplementary Table 1). The GWAS from Iceland was performed
using 32 million markers identified through whole-genome
sequencing of 15,220 Icelanders that were subsequently imputed
into 151,677 chip-typed individuals, as well as 282,894 of their
first and second degree relatives7. The GWAS from the UK was
performed with 40 million markers (imputation info > 0.8) from
the Haplotype Reference Consortium (HRC) reference panel,
imputed into chip-typed individuals of European ancestry in the
UK Biobank11 (Fig. 1). Associations were considered significant if
the p-value in the combined dataset was below a weighted
genome-wide significance threshold based on variant annota-
tion12. The significance thresholds used were 2.0 × 10–7 for high-
impact variants (including stop-gained, frameshift, splice acceptor
or donor, N= 11,465), 3.9 × 10–8 for moderate-impact variants
(including missense, splice-region variants and in-frame indels,
N= 197,583), 3.6 × 10–9 for low-impact variants (including
upstream and downstream variants, N= 2,971,445) and 5.9 ×
10–10 for lowest-impact variants (including intron and intergenic
variants, N= 39,726,619). In total, 43 million markers were tested
in the meta-analysis.
We found 32 gallstone disease association signals at 28 loci
(Table 1, Supplementary Table 2, Fig. 2, and Supplementary Data 1)
that reached genome-wide significance under the additive model.
Of these, 21 are novel and 11 correspond to previously known
variants5,8,9,13. One of the novel common variants, rs708686
upstream of FUT6, associates more significantly with gallstone
disease through a recessive mode of inheritance. There was no
significant heterogeneity of effects between Iceland and the UK
(Table 1, Supplementary Data 1). Thirteen of the novel signals
represent associations with coding variants, four of which are low
frequency coding variants, with minor allele frequency (MAF)
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Fig. 1 A flowchart describing the study design of the gallstone meta-analysis of Icelandic and UK Biobank data and results
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and UK). Three novel gallstone-associated non-coding variants at
the LITAF and MAL2 loci and a stop gained variant at the FUT2
locus are correlated with (r2 > 0.8) or represent the strongest cis-
eQTLs in their respective regions (Table 1, Supplementary Table 3).
We tested the 32 gallstone disease variants for association with
five other related diseases of the biliary system (acute pancreatitis
[N= 3401], cholecystitis [N= 3565], fibrosis/cirrhosis of liver [N
= 1044], cholestasis of pregnancy [N= 2615], and gallbladder
cancer [N= 382]), six liver biomarkers (alanine aminotransferase
[ALT; N= 172,086], aspartate aminotransferase [AST; N=
164,467], gamma glutamyltransferase [GGT; N= 156,692], alka-
line phosphatase [ALP; N= 154,097], albumin [N= 92,163], and
bilirubin [N= 109,748]), and four lipid traits (high-density
lipoprotein [HDL cholesterol; N= 136,736], low-density lipopro-
tein [LDL cholesterol; N= 126,220], total cholesterol [N=
150,211]) and triglycerides [N= 119,624], resulting in a total of
32 × (5+ 6+ 4)= 480 tests that had to be accounted for in the
assessment of significance (Supplementary Data 2 and Supple-
mentary Data 3). We observed five significant associations: the
Pro290Ser missense variant in SLC10A2 associates with an
increased risk of acute pancreatitis (see below), the previously
reported8 Asp19His missense variant in ABCG8 also associates
with increased risk of acute pancreatitis and cholecystitis, and the
two rare coding variants we reported in ABCB4 (Leu445Glyf-
sTer22/rs756082276[CCT] andGly622Glu/rs756935975[T]) both
associate with high risk of cholestasis of pregnancy, as previously
reported7 (Supplementary Data 2). Ten gallstone disease variants
associate with ALT, seven with AST, fourteen with GGT, nine
with ALP, two with albumin, and two with bilirubin (Supple-
mentary Data 3). Four variants associate with HDL cholesterol,
six with LDL cholesterol, nine with total cholesterol and six with
triglycerides (Supplementary Data 3).
The sibling recurrence risk of gallstone disease in the Icelandic
population is 1.81 [1.71, 1.91], in line with reported estimates14
(Supplementary Data 4). Combined, the 32 gallstone disease
variants account for a sibling recurrence risk of 1.13 (Supple-
mentary Data 4).
Low-frequency coding variants in SLC10A2. We found two
distinct missense variants in SLC10A2 (Pro290Ser and Val98Ile;
r2 < 0.001) associating with increased risk of gallstone disease
(Table 1, Supplementary Table 4). The SLC10A2 gene encodes the
apical sodium-dependent bile acid transporter (ASBT), also
known as the ileal sodium-dependent bile acid transporter (ISBT)
that mediates the intestinal reabsorption of bile acids.
The variant in SLC10A2 with the strongest effect on gallstone
disease risk is Pro290Ser (rs56398830[A]; OR= 1.36 [1.25–1.49];
P= 2.1 × 10–12, MAFIceland= 0.6%, MAFUK= 1.1%) (Table 1,
Supplementary Fig. 1 and Supplementary Data 1). Others have
experimentally shown that Pro290Ser nearly abolishes the bile
acid transport activity of ASBT15,16 ( < 3% of the wild-type
level16). Pro290Ser is in transmembrane domain seven which is
highly conserved within the SLC10 family of proteins, and results
in a substitution of a non-polar proline with a polar serine17
(PolyPhen-2: probably damaging, SIFT: deleterious) (Fig. 3a). We
observe 62 homozygous carriers of Pro290Ser (expected number
of homozygous carriers under Hardy-Weinberg (HW) equili-
brium= 55); of whom eight carry a diagnosis of gallstone disease.
The gallstone disease odds ratio for homozygous carriers of
Pro290Ser is 3.26 [1.55–6.86], consistent with the additive model
(Supplementary Fig 2a). Homozygotes are expected to have very
little ASBT/SLC10A2 transport activity.
In a meta-analysis of acute pancreatitis in Iceland (1366 cases
and 361,081 controls) and UK (1477 cases and 407,090 controls),
we detected an association of Pro290Ser with increased risk of
this disease (OR= 1.76 [1.38–2.24], P= 5.6 × 10–6, Supplemen-
tary Fig. 3 and Supplementary Data 2). Among the 32 gallstone-
associated variants, effects on gallstone disease and acute
pancreatitis were positively correlated (r= 0.81 [0.69–0.92]; P
Table 1 Novel gallstone disease associated variants found in the meta-analysis of Icelandic and UK Biobank data
Marker Position (Hg38) min/maj MAF (%) Variant Gene LD-class (HIGH/
MOD/LOW/
LOWEST)
OR (95% CI) P-value Phet Functional support
rs1800961 chr20:44413724 T/C 4.6 Thr139Ile HNF4A 1 (0/1/0/0) 1.29 [1.23,1.35] 5.7 × 10–26 0.23 Master regulator of liver specific genes
rs28929474* chr14:94378610 T/C 0.81 Glu366Lys SERPINA1 2 (0/1/1/0) 1.33 [1.25,1.42] 1.8 × 10–17 0.27 OMIM:613490 alpha-1-antitrypsin deficiency
rs56398830 chr13:103049340 A/G 0.59 Pro290Ser SLC10A2 2 (0/1/0/1) 1.36 [1.25,1.49] 2.1 × 10–12 0.14 OMIM:613291 primary bile acid malabsorption
rs55971546 chr13:103065958 T/C 4.1 Val98Ile SLC10A2 1 (0/1/0/0) 1.15 [1.10,1.20] 1.8 × 10–10 0.97 OMIM:613291 primary bile acid malabsorption
rs2291428 chr10:45463408 C/G 22 Phe277Leu MARCH8‡ 42 (0/2/2/38) 1.12 [1.10,1.15] 2.4 × 10–27 0.55 Associated with lipid levels
rs2290846 chr4:150277928 A/G 28 Ser2797Leu LRBA‡ 25 (0/2/4/19) 1.12 [1.09,1.14] 4.7 × 10–27 0.23
rs601338*** chr19:48703417 G/A 39 Trp154Ter FUT2 48 (1/1/43/3) 0.91 [0.90,0.93] 9.4 × 10–22 0.02 Lewis and ABO(H) histo-blood group antigen
secretor allele; cis-eQTL associated with decreased
expression of FUT2 in esophagus (mucosa) and
other tissues#
rs708686** chr19:5840608 T/C 23 upstream FUT6 1 (0/0/1/0) 1.26 [1.20,1.32] 7.4 × 10–20 0.84
rs34851490 chr19:45881296 G/A 8.5 downstream IRF2BP1 28 (0/0/17/11) 1.12 [1.09,1.16] 4.2 × 10–15 0.82
rs1169288 chr12:120978847 C/A 31 Ile27Leu HNF1A 21 (0/1/2/18) 0.92 [0.91,0.94] 1.6 × 10–14 0.07 Master regulator of liver specific genes
rs13280055 chr8:11664844 A/G 13 intergenic - 3 (0/0/0/3) 1.11 [1.08,1.14] 6.9 × 10–14 0.90
rs174567 chr11:61825533 G/A 39 upstream FADS2 59 (0/0/29/30) 1.07 [1.05,1.09] 2.3 × 10–12 0.89 Bile acid metabolism
rs11012737 chr10:21560840 A/G 27 downstream MLLT10 89 (0/0/14/75) 1.07 [1.05,1.10] 3.7 × 10–12 0.37
rs2469991 chr8:119335236 T/A 32 intergenic MAL2 31 (0/0/3/28) 0.93 [0.91,0.95] 9.2 × 10–12 0.60 Cis-eQTL associated with decreased expression of
MAL2 in adipose tissue#
rs1935 chr10:63168063 C/G 48 Glu2353Asp JMJD1C 166 (0/1/11/154) 1.07 [1.05,1.09] 9.2 × 10–12 0.04 Associated with lipid levels
rs17240268 chr15:89804583 A/G 12 Ala311Val ANPEP 16 (0/1/3/12) 0.90 [0.87,0.93] 6.0 × 10–11 0.12 Promotes in-vitro cholesterol crystallization
(PMID:8102610)
rs12004 chr22:38481456 G/T 31 Val199Gly KDELR3 237 (0/1/91/145) 1.07 [1.04,1.09] 1.2 × 10–10 0.78
rs11641445 chr16:11545628 T/C 34 downstream LITAF 48 (0/0/9/39) 1.06 [1.04,1.09] 4.2 × 10–10 0.57 Cis-eQTL associated with decreased expression
of LITAF in adipose and liver tissue#
rs17138478 chr17:37713312 A/C 13 intron HNF1B 1 (0/0/0/1) 1.09 [1.06,1.12] 5.1 × 10–10 0.17 Master regulator of liver specific genes
rs2292553 chr2:218282080 G/A 46 Pro21Leu TMBIM1† 166 (0/3/40/123) 0.95 [0.93,0.97] 1.1 × 10–8 0.79
rs12968116 chr18:57655270 T/C 16 Arg952Gln ATP8B1 18 (0/1/4/13) 0.92 [0.90,0.95] 1.2 × 10–8 0.26 OMIM:211600 cholestasis, progressive familial
intrahepatic 1
Note: Samples from Iceland (Ncases= 8757 and Ncontrols= 346,688), UK Biobank (Ncases= 18,417 and Ncontrols= 390,150), in total Ncases= 27,174 and Ncontrols= 736,838. Effect is shown for the minor
allele. Significance levels and effects are shown for the combined analysis. LD-class: total number of variants with R2 > 0.8 (stratified by functional impact class, where HIGH impact variants include stop-
gained, frameshift, splice acceptor or donor; MODerate impact variants include missense, splice-region variants and in-frame indels; LOW impact variants include upstream and downstream variants;
and LOWEST impact variants include intron and intergenic variants), MAF: Minor allele frequency in Iceland, min: Minor allele, maj: Major allele, OR: Odds ratio, CI: Confidence interval, Phet: P-value for
test of heterogeneity between Iceland and UK. The four low-frequency variants (with MAF < 5%) are shown at the top of the table
*Corresponds to the PI Z allele of SERPINA1, **results for FUT6 are based on a recessive model of inheritance, ***the tested allele rs601338[G] corresponds to the classical wild-type secretor allele of
FUT2, †the LD-class contains moderate impact variants in two separate genes (a missense variant in TMBIM1 and two splice-region variants in ARPC2), ‡the LD-class contains two moderate impact
variants in the same gene, #see Supplementary Table 3 for details on cis-eQTL
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= 1.7 × 10–8, Supplementary Fig. 3). Since ASBT is a bile acid
transporter that mainly transports taurocholate, we tested the
effect of Pro290Ser in serum levels of taurocholate (N= 273
including four carriers of Pro290Ser). As expected, Pro290Ser
associates with reduced levels of serum taurocholate (Effect: −1.6
SD [−2.56, −0.64]; P= 0.0010; Supplementary Table 5). We also
tested for an effect of Pro290Ser on fibroblast growth factor 19
(FGF19, N= 293), a hormone that regulates bile acid synthesis18,
and observed no effect (Effect: −0.08 SD [−1.02, 0.87]; P= 0.87;
Supplementary Table 5). Despite a large sample size, we observed
no association with other liver biomarkers in the Icelandic data
(Supplementary Data 3).
A more common SLC10A2 missense variant, Val98Ile
(rs55971546[T]), also associates with increased risk of gallstone
disease (OR= 1.15 [1.10–1.20], P= 1.8 × 10–10, MAF= 4.1% in
both Iceland and the UK) (Table 1, Supplementary Table 4 and
Supplementary Data 1). Val98Ile is located in transmembrane
domain two and has been shown experimentally by others to
reduce the transport activity by 42%16.
The abovementioned study16 reported transport activity for
Pro290Ser and Val98Ile, as well as two other ASBT/SLC10A2
variants, Val159Ile (rs60380208[T]) and Ser171Ala (rs188096
[A]). For each of these missense variants, we compared the
previously reported transport activity measurements to their
effect on gallstone disease risk from the current study (Fig. 3b).
Lower transport activity is correlated with greater risk of gallstone
disease (r=−0.99 [−1.00, −0.66], p= 8.2 × 10–3 for OR vs.
activity; r=−0.99 [−1.00, −0.77], p= 5.2 × 10–3 for log(OR) vs.
activity). Additionally, we show transport activity compared to
the genotypic risk of gallstone disease for different genotypes of
Pro290Ser, Val98Ile and wild-type (Supplementary Fig. 4).
Together these data indicate that the variants in SLC10A2 affect
gallstone risk through impairment of the bile acid reabsorption
function of ASBT.
We found 17 other missense variants in SLC10A2 (Supple-
mentary Table 6). Of these, one additional variant, Pro65Leu
(MAFIceland= 0.26%; MAFUK= 0.14%), associates with gallstone
disease given the number of tested markers (significance thresh-
old: P < 0.05/17= 0.0029) (OR= 1.40 [1.15–1.72], P= 0.00096).
Finally, it is worth noting that a truncating variant in SLC10A2
(not found in our data) has been claimed to cause hypertrigly-
ceridemia19. In our data the SLC10A2 variants Pro290Ser and
Val98Ile (which were shown experimentally16 to have abolished
and reduced function, respectively) do not associate (P > 0.4 for
both variants) with hypertriglyceridemia, defined as having at
least two serum triglyceride measurements higher than 5 mmol/L
(N= 1,599; Supplementary Data 5). Thus, our data do not
support the claim that loss-of-function variants in SLC10A2 cause
hypertriglyceridemia.
Low-frequency coding variant in SERPINA1. A low-frequency
missense variant Glu366Lys (rs28929474[T]) in SERPINA1,
encoding the protease inhibitor alpha-1-antitrypsin (AAT),
associates with increased risk of gallstone disease (OR= 1.33
[1.25–1.42], P= 1.8 × 10–17, MAFIceland= 0.8%, MAFUK= 1.9%)
(Table 1, Supplementary Fig. 6 and Supplementary Data 1).
Gly366Lys is also known as the Protease Inhibitor (PI) Z allele
and causes severe alpha-1 antitrypsin deficiency (AATD) in
homozygotes20. The most common clinical manifestations of
AATD are emphysema and chronic obstructive pulmonary dis-
ease (COPD), and a subset of AATD cases develop liver cirrhosis
and fibrosis21. Consistent with this, in a meta-analysis of Ice-
landic and UK Biobank emphysema and COPD data, the PI Z











































Fig. 2 Manhattan plot for gallstone disease meta-analysis association results (Ncases= 27,174 and Ncontrols= 736,838). Variants are plotted by
chromosomal position (x-axis) and −log10 P-values (y-axis). A chi-square test was used when testing for association. Green=Novel loci represented by
low-frequency variants, red= novel loci represented by common variants, blue= reported gallstone disease loci
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[17.5–43.7], P= 6.8 × 10–46) and COPD (OR= 4.84 [2.97–7.90],
P= 2.8 × 10–10) in homozygotes. As previously reported22,23,
heterozygous carriers of PI Z also are at increased risk of
emphysema (OR= 1.44 [1.21–1.70], P= 3.0 × 10–5, Table 2).
We tested the association of PI Z with liver biomarkers in the
Icelandic data (Supplementary Table 7 and Supplementary
Data 3). PI Z associates with decreased alpha-1-antitrypsin and
alpha-fetoprotein levels; and increased levels of alkaline phos-
phatase, alanine transaminase, gamma glutamyl transpeptidase
and increased platelet count, consistent with previous reports20,24.
We observe four homozygous carriers (PI ZZ) in Iceland and
156 in the UK, compared to 10 and 145 expected under HW
equilibrium, respectively. None of the Icelanders and nine of the
UK individuals have a gallstone disease diagnosis, and all but one
have undergone cholecystectomy indicating symptomatic disease
(Supplementary Table 8). To investigate to what extent the
observed associations are driven by PI Z allele homozygotes, we
calculated the genotypic odds ratios for gallstone disease,
emphysema and COPD, based on genotypes of the classical M,
S, and Z alleles (Table 2, Supplementary Fig. 2b, 7 and 8). In line
with the literature, the genotypic effect was consistent with a
recessive trend and a compound heterozygote effect of MZ for
emphysema and COPD (OMIM: 613490). However, the geno-
typic effect on gallstone disease was consistent with an additive
model.
In addition to PI Z, the PI S allele in SERPINA1 (Glu288Val),
which is one of the most common AATD deficiency alleles,
associates with an increased risk of gallstone disease under the
additive model (OR= 1.08 [1.03–1.13], P= 4.8 × 10–4).
Low-frequency coding variant in HNF4A. A low-frequency
missense variant, Thr139Ile (rs1800961[T]), in HNF4A associates
with increased risk of gallstone disease (OR= 1.29 [1.23–1.35], P
= 5.7 × 10–26). Thr139Ile has a MAF of 4.6% in Iceland and 3.0%
in the UK (Table 1, Supplementary Data 1 and Supplementary
Fig. 9). HNF4A encodes the hepatocyte nuclear factor 4α, a
master regulator of liver-specific gene expression, especially of
genes involved in lipid transport and glucose and bile metabo-
lism25. Thr139Ile has been associated with a reduction in high
density lipoprotein (HDL) cholesterol and total cholesterol
levels26. In addition, we observe an association of Thr139Ile with
increased hemoglobin, bilirubin and gamma glutamyl transpep-
tidase levels (Supplementary Table 9). In-vitro reporter assays
indicate that Thr139Ile decreases the ability of HNF4A to activate
transcription27,28.
Common variant associations. Seventeen novel common
sequence variants (MAF > 5%) associate with gallstone disease
(Supplementary Data 1). One of these, rs708686[T] upstream of
FUT6, fits better a recessive rather than an additive model
(MAFIceland= 23%, homozygous frequency= 5.3%), and associ-
ates with increased risk of gallstone disease (ORrecessive= 1.26
[1.20–1.32], Precessive= 7.4 × 10–20; ORadditive= 1.08 [1.06–1.10],
Padditive= 2.3 × 10–12). There is no difference between the risk to
heterozygous carriers of rs708686[T] and non-carriers (Supple-
mentary Fig. 10). We have previously reported rs708686[T] to
associate with increased levels of vitamin B1229 (Supplementary
Data 6). Similarly with what we see for gallstone disease, we
observed a trend towards recessive association of rs708686 with
vitamin B12 levels (Supplementary Fig. 11).
Ten of the 17 common signals represent coding variants: one
stop-gained (FUT2) and nine missense (Table 1 and Supplemen-
tary Data 1). We observe an association of the variant rs601338
[G] in FUT2, corresponding to the primary Lewis and ABO(H)
histo-blood group antigen secretor allele, with reduced risk of
gallstone disease (OR= 0.91 [0.90–0.93], P= 9.4 × 10–22). The
wild-type secretor allele rs601338[G] has been implicated in
susceptibility to gastrointestinal infections30,31, decreased vitamin
B12 levels32 and with effects on several diseases and other traits33
(Supplementary Data 6). Consistent with previous observations,
rs601338[G] associates with increased risk of gastrointestinal
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Fig. 3 SLC10A2 transport activity and gallstone risk. a Schematic illustration of the topology of the SLC10A2 protein showing the localization of the
functionally assessed missense variants Pro290Ser, Val98Ile, Val159Ile, and Ser171Ala (from PMID: 19823678). b A scatter plot showing four SLC10A2
missense variants Pro290Ser, Val98Ile, Val159Ile, and Ser171Ala. The x-axis shows the bile acid transport activity (from PMID:21649730) while the y-axis
shows the odds ratio for gallstone disease in the Iceland+UK meta-analysis (Ncases= 27,174, Ncontrols= 736,838)
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[1.34–1.82], P= 7.2 × 10–9) (Supplementary Table 10). In Iceland
we also observe an effect of rs601338[G] on decreased gamma
glutamyl transferase and increased folate (Supplementary
Table 10). FUT2 is a paralog of the previously mentioned FUT6
and they both belong to the gene family of fucosyltransferases
(63% identical on the protein level).
Of note, Ala311Val (rs17240268[A]) in ANPEP (aka CD13)
associates with decreased risk of gallstone disease (OR= 0.90
[0.87–0.93], P= 6.0 × 10–11). This gene encodes Aminopeptidase
N, which has been reported to promote cholesterol crystallization
in in-vitro systems34 and through that may affect cholesterol
gallstone formation35. The minor allele rs17240268[A] would be
expected to have a reducing effect on protein function for the
observed protective effect on gallstone disease to be consistent
with the reported promoting effect of ANPEP on cholesterol
crystallization.
In addition to the hepatocyte nuclear factor HNF4A (see
above), we observe signals in two other hepatocyte nuclear factor
genes. The missense variant Ile27Leu (rs1169288[C]) in HNF1A
associates with decreased risk of gallstone disease (OR= 0.92
[0.91–0.94], P= 6.0 × 10–11). HNF1A encodes the hepatocyte
nuclear factor 1α and is involved in the regulation of the
expression of several liver-specific genes36 and bile acid
transporters, including ASBT, in the enterocytes of the terminal
ileum37. Ile27Leu has been associated with higher LDL cholesterol
levels38,39 and increased risk of coronary artery disease40
(Supplementary Data 6). Diabetes, hypercholesterolemia and
increased bile acid and cholesterol synthesis were observed in
mice deficient for HNF1A37. An intron variant rs17138478[A] in
HNF1B associates with increased risk of gallstone disease (OR=
1.09 [1.06–1.12], P= 5.1 × 10–10). The variant falls within a liver
specific enhancer element controlling the expression of itself and
has HNF4A among its DNA binding proteins (Supplementary
Data 7).
Lipid variants and gallstone disease. The biological functions of
the 32 gallstone associated variants were assessed by gene
enrichment analysis using ToppGene41. Variants were assigned to
genes if they were located inside the gene or located within 5 kbs
upstream and downstream from a gene, on the basis of mappings
from previous GWAS studies or based on evidence from eQTL
data (GTEx). In total 31 variants could be assigned to 27 genes
that were included in the subsequent analysis (see Supplementary
Data 8 for inclusion criteria). The analysis revealed enrichment of
genes at loci reported to associate with lipid levels
(PMID:24097068, P= 2.5 × 10–18, 11 out of 212 genes), in addi-
tion to genes linked to bile secretion (KEGG:193146, P= 7.6 ×
10–8, 5 out of 71 genes) and maturity onset diabetes of the young
(KEGG:83096, P= 9.0 × 10–6, 3 out of 26 genes). Based on these
results and because of the high cholesterol content of most gall-
stones, we tested 203 variants representing signals reported to
associate with either HDL cholesterol, LDL cholesterol, total
cholesterol or triglyceride serum levels for risk of gallstone disease
(Supplementary Data 9). There is an excess of gallstone associated
variants among reported HDL cholesterol, LDL cholesterol and
total cholesterol associated variants: eight out of 83 HDL cho-
lesterol variants (P= 5.3 × 10–19 based on a binomial test, see
Methods), nine out of 65 LDL cholesterol variants (P= 1.1 ×
10–22), fourteen out of 77 total cholesterol variants (P= 2.5 ×
10–36) and five out of 49 triglyceride variants (P= 1.2 × 10–12)
also associate with gallstone disease when all 203 tests are
accounted for in the assessment of significance. In total, 23 of the
203 unique variants associating with one or more of HDL cho-
lesterol, LDL cholesterol, total cholesterol and triglycerides also
associate with gallstone disease. However, there is no consistency
in the directions of the effects on serum cholesterol and gallstone
disease risk (Fig. 4). This indicates that lipid serum levels are not
by themselves causative factors in gallstone formation, even
though cholesterol metabolism appears to have an impact on
gallstone risk.
Of note is that a missense variant Gln535Arg in DAGLB
(rs2303361[C]), encoding diacylglycerol lipase beta, associates
with an increased risk of gallstone disease (OR= 1.06 [1.04–1.08],
P= 4.7 × 10–8). The variant is in strong LD (r2= 0.95) with the
intron variant rs1880118[C] that was recently reported to
associate with increased HDL cholesterol levels and increased
DAGLB expression in subcutaneous adipose tissue42. We replicate
the association of rs1880118[C] with increased HDL cholesterol
in our data (effect= 0.15 SD [0.10–0.20], P= 2.4 × 10–9).
Diabetes and gallstone disease. The relationship between gall-
stone disease and diabetes is not clear43. To explore whether there
is a difference in the effect of gallstone associated sequence var-
iants between diabetics and non-diabetics, we tested whether the
32 gallstone disease associated variants confer different risk on
diabetics and non-diabetics and found no significant differences
(Supplementary Fig. 12). To further explore the relationship of
gallstone disease and genes linked to maturity onset diabetes of
the young (MODY), we tested 12,809 variants in 12 genes linked
to MODY (including 36 known pathogenic MODY variants) for
association with gallstone disease; no additional signals associat-
ing with gallstone disease were observed (Supplementary
Data 10).
Self-report vs. hospital diagnosis. Since 4067 of the 18,417 UK
cases are based only on self-reporting, we have looked for a dif-
ference between association results for self-reported and ICD10-
diagnosed cases. There is no difference between effect sizes in the
Table 2 Effect of alpha-1-antitrypsin genotypes on A1AT levels, gallstone disease, emphysema and COPD













OR [95% CI] P OR [95% CI] P OR [95% CI] P
MM 628,272 89 157 [105–309] 149 [100–273] – – – – – –
MS 55,893 7.9 130 [88–256] 126 [84–225] 1.06 [0.99–1.14] 0.10 1.10 [0.97–1.24] 0.12 0.93 [0.88–0.99] 0.014
MZ 20,136 2.8 95 [64–187] 89 [61–156] 1.34 [1.26–1.43] 3.9 × 10–21 1.44 [1.21–1.70] 3.0 × 10–5 0.97 [0.89–1.07] 0.58
SS 1248 0.18 110 [88–147] 95 [49–181] 1.11 [0.85–1.45] 0.44 0.83 [0.34–2.00] 0.68 1.10 [0.78–1.55] 0.60
SZ 975 0.14 63 [59–82] 64 [42–108] 1.36 [1.04–1.79] 0.027 1.06 [0.44–2.57] 0.89 1.02 [0.68–1.53] 0.94
ZZ 164 0.023 –** 25 [15–57] 1.29 [0.66–2.52] 0.46 27.7 [17.5–43.7] 6.8 × 10–46 4.84 [2.97–7.90] 2.8 × 10–10
N number of individuals with each genotype, Freq genotype frequency for combined set, OR odds ratio comparing each genotype to MM, CI 95% confidence interval for the odds ratio
*Donato et al. refer to A1AT measurements in Table 3 of PMID:22912357
**No PI ZZ carriers had A1AT measurements in the Icelandic dataset
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two groups (ICD10 and self-reported) for 30 of the 32 variants
found. The two variants with a significant difference between
ICD10-based and self-reported-based effects are the novel gall-
stone disease associated variant SERPINA1 Glu366Lys (PI Z;
rs28929474[T]) (P-value for test for heterogeneity: Phet= 2.2 ×
10–4) and the previously reported ABCG8 Asp19His (rs11887534
[C], Phet= 1.6 × 10–9) missense variants, which both showed a
larger effect when using self-reported cases than ICD10 code
cases. However, both these variants associate with both ICD10-
based and self-reported gallstone disease (Supplementary Fig. 13,
Supplementary Table 11).
Discussion
Through a GWAS of gallstone disease in Iceland and UK, we
found 21 novel sequence variants that associate with the disease,
including four low frequency coding variants in SLC10A2 (two
distinct variants), HNF4A and SERPINA1 with relatively large
effects.
Most notably, we demonstrate that two distinct low-
frequency missense variants in the bile acid transporter
SLC10A2 — Pro290Ser and Val98Ile — associate with higher
risk of gallstone disease. The variants have experimentally been
shown to reduce the transport activity of the protein encoded
by the gene, commonly known as ASBT16. We observe a ten-
dency to a higher risk of gallstone to associate with a lower
transport activity of different variants of SLC10A2. The main
function of ASBT is to reabsorb bile salts (up to 95%) from the
terminal ileum into ileocytes, after which the bile salts are
transported back to the liver through the enterohepatic circu-
lation44. We postulate that impairment of ASBT leads to dis-
turbances of the enterohepatic circulation, causing imbalances
of the relative amounts of bile acids, cholesterol and phos-
pholipids, thus increasing the risk of gallstone formation.
Because of its role in the enterohepatic circulation, a connection
between SLC10A2 and gallstone disease risk has been postu-
lated. In a candidate gene study45 with 240 gallstone cases and
255 controls, the rs9514089[C] SLC10A2 intron variant was
reported to associate with an increased risk of gallstone disease
(OR= 2.04 [1.19–3.55]; P= 7.7 × 10–3). The reported p-value
does not survive multiple testing correction accounting for the
30 markers tested in their manuscript. A subsequent study46
found no association of rs9514089 with gallstone disease (OR
a
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Fig. 4 203 variants reported to be associated with either HDL cholesterol, LDL cholesterol, total cholesterol or triglyceride levels: Effect of the allele
associated with an increased level of serum lipids vs. odds ratio (OR) for gallstone disease, for a) HDL cholesterol, b) LDL cholesterol, c) total cholesterol,
and d) triglycerides. Crosses indicate 95% confidence intervals. Variants with a significant OR for gallstone disease (P < 0.05/203= 2.6 × 10‒4) are shown
in red
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= 0.83 [0.63–1.09]; P= 0.19), and this variant has not been
reported to associate with gallstone disease by others7–10. In our
Icelandic and UK data (with 27,174 cases) we find no associa-
tion between rs9514089[C] and gallstone disease risk (OR=
0.991 [0.973–1.010]; P= 0.36; Supplementary Table 12). Thus,
we conclude that the claimed association of rs9514089 with
gallstone disease is a false positive. Other coding variants in
SLC10A2 have been implicated in primary bile acid malab-
sorption, based on a single pedigree with one identified com-
pound heterozygous carrier of a missense and a splice-donor
variant47. SLC10A2 inhibitors have previously been considered
as a therapeutic candidate for type 2 diabetes48, but are now
pursued as a treatment of chronic constipation due to the
initially unwanted diarrhea and steatorrhea side-effects49. Our
results indicate that inhibition of SLC10A2 associates with
higher risk of gallstone disease as homozygotes for Pro290Ser
(expected to have less than 3% transport activity16) have an
odds ratio of 3.26 [1.55–6.86]. The genes ABCB4 and SULT2A1,
previously reported to be associated with gallstone disease, are
also involved in bile homeostasis8,13.
A number of the novel variants described here to associate with
gallstone disease are at loci linked to Mendelian diseases: Inter-
estingly, the hepatocyte nuclear factors HNF1A, HNF1B, and
HNF4A are all linked to autosomal dominant forms of maturity-
onset diabetes of the young (MODY3, OMIM:600496; MODY5,
OMIM:137920; and MODY1, OMIM:125850; respectively). In
addition, among the reported gallstone loci, the glucokinase
regulatory protein (GCKR) is a regulator of glucokinase (GCK),
that is linked to MODY2 (OMIM:125851).
Among the novel gallstone variants, two are in fucosyl-
transferase genes (FUT2 and FUT6). Fucosyltransferases mediate
fucosylation which is an abundant posttranslational modification
of glycosylated proteins and lipids. FUT2 is responsible for the
majority of fucosylation in the gastrointestinal tract50,51. Inter-
estingly, we observe opposing effects of the FUT2 variant
rs601338 on the risk of gallstone disease and susceptibility to
gastrointestinal infection. This constitutes an example of antag-
onistic pleiotropy where a variant has opposing effects on the risk
of two diseases. The increased risk of gastrointestinal infection
observed for the wild-type secretor allele rs601338[G] is likely due
to the presence of fucosylated glycans in the gastrointestinal tract
that serve as adhesion sites for pathogens. FUT2 may influence
biliary disease progression through interaction with the biliary
and intestinal microbiota52,53. However, the mechanism through
which the rs601338 variant influences the risk of gallstone disease
is unclear, as the FUT2 locus is highly pleiotropic and is the
subject of balancing selection in humans54,55. Further investiga-
tion is needed to explain the role of fucosylation in the patho-
genesis of gallstone disease.
We show that the PI Z allele of SERPINA1 associates with
increased risk of gallstone disease. Severe AAT deficiency in PI
ZZ homozygotes predisposes to emphysema and, less commonly,
to liver disease20. The precise pathomechanism of liver disease
associated with severe AAT deficiency is not well understood but
histopathological findings of liver parenchyma in PI ZZ homo-
zygotes indicate that liver abnormalities result from toxic intra-
cellular accumulation of AAT in hepatocytes56. Moderate AAT
deficiency in PI MZ heterozygotes has been associated with
slightly increased risk of liver disease and intracellular accumu-
lation of AAT in hepatocytes57. We speculate that MZ hetero-
zygosity may result in general liver dysfunction as result of toxic
accumulation of AAT in hepatocytes over time, thus predisposing
to gallstone disease.
Biliary cholesterol secretion plays a major role in cholesterol
homeostasis58. Variants in genes involved in cholesterol home-
ostasis, including ABCG5/ABCG8 and CYP7A1, are reported to
associate with gallstone disease8. Six of the novel gallstone asso-
ciated variants, or highly correlated variants (r2 > 0.8), have been
reported to associate with blood cholesterol levels (in HNF4A,
HNF1A, FUT2, FADS2, MARCH8, and JMJD1C) (Supplementary
Data 9). Most notably, HNF4A is a nuclear receptor highly
expressed in the liver, and has been shown to control the
expression of the closely linked cholesterol transporters ABCG5
and ABCG8 that share a promotor59. Despite a clear role of the
aforementioned genes in cholesterol homeostasis, it remains
unclear whether serum cholesterol levels affect risk of gallstone
disease60. When considering 203 variants reported to associate
with serum HDL cholesterol, LDL cholesterol, total cholesterol or
triglyceride levels we do not observe a consistent direction of
effect of lipid increasing alleles on the risk of gallstone disease.
This suggests that there is not a direct path between serum lipid
levels and the production of gallstones, which is in line with
observations from previous studies61.
While our data, as well as data from others61, do not support a
direct path between serum cholesterol levels and gallstone for-
mation, some aspects of cholesterol metabolism may contribute
to gallstone disease. Biliary cholesterol super-saturation is con-
sidered a major factor in promoting cholesterol nucleation and
gallstone formation62–64. Thus sequence variants affecting the
amount of cholesterol secreted into bile, or the cholesterol/bile
acid ratio, are likely to impact gallstone formation. Depending on
the mechanism of action of the cholesterol regulating genes, the
allele associated with gallstone risk may not consistently decrease
or increase serum cholesterol levels. For example, increased
activity of the sterol-transporter ABCG5/8 that has a direct role in
promoting biliary cholesterol secretion and in reducing intestinal
absorption of dietary cholesterol is expected to increase the risk of
gallstones while lowering circulating cholesterol. In contrast,
reduced function of CYP7A1, the rate-limiting enzyme in the
conversion of cholesterol to bile acids in the liver, likely predis-
poses to gallstone formation through a decrease in bile acid
synthesis. It has been postulated that the increase in serum
cholesterol levels that has been observed in carriers of CYP7A1
gallstone risk variants may be mediated through down-regulation
of hepatic LDL receptors65.
In summary, we have discovered 21 novel gallstone disease
variants in the largest gallstone disease GWAS to date. The
associations presented emphasize the role of sequence variants in
genes involved in cholesterol homeostasis and specifically high-
light the intestinal compartment of the enterohepatic circulation
in the pathogenesis of gallstone disease. We conclude that
sequence variants affecting the amount of cholesterol secreted
into bile, or the cholesterol/bile acid ratio, are likely to cause
gallstone formation.
Methods
Study subjects from Iceland. This study is based on whole-genome sequence data
from the whole blood of 15,220 Icelanders participating in different disease projects
at deCODE genetics. Additionally, 151,677 Icelanders have been genotyped using
Illumina SNP chips and genotype probabilities for untyped relatives have been
calculated based on Icelandic genealogy. The process used to whole-genome
sequence the Icelandic population, and the subsequent imputation from which the
data for this analysis were generated, has been comprehensively described in a
recent publication7. We note that selection of individuals for whole-genome
sequencing and chip genotyping was not performed with regards to gallstone case
status.
All individuals who donated blood, or their guardians, provided written
informed consent. All sample identifiers have been encrypted, in accordance with
the regulations of the Icelandic Data Protection Authority. The study was approved
by the National Bioethics Committee (ref:VSNb2015100030/03.03). Personal
identities of the participants and biological samples were encrypted using a third-
party system approved and monitored by the Icelandic Data Protection Authority.
The National Bioethics Committee approved the study, including the protocol,
methodology and all documents presented to the participants. All methods were
performed in accordance with the relevant guidelines and regulations.
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To identify gallstone cases, we searched for patients with International
Classification of Diseases (ICD) codes, diagnosis code ICD-10 K80 Cholelithiasis
and ICD-9 574, indicative of gallstone disease, at Landspitali—The National
University Hospital of Iceland in Reykjavik (LUH), and the Icelandic Medical
Center in Mjodd (Laeknasetrid). A total of 8757 gallstone cases were included in
the association analysis; 892 of these were whole-genome sequenced, 5840 were
genotyped using various Illumina chips and imputed using long-range phased
haplotypes, and genotype probabilities for 2026 were imputed on the basis of
information from genotyped close relatives. In addition, cases of five diseases of the
biliary system were identified by the ICD codes K85 for acute pancreatitis, K81 for
cholecystitis, K74 for fibrosis/cirrhosis of liver, O26.6 for cholestasis of pregnancy
and C23 for gallbladder cancer. Individuals recruited through different genetic
research projects at deCODE were used as controls, and individuals in the gallstone
cohort were excluded from the control group. Among the controls, 13,204 were
whole-genome sequenced, 133,026 were genotyped by chip, and 200,458 were
imputed on the basis of the genotypes of close relatives. In total, the number of
controls was 346,688.
Study subjects from the UK. The UK Biobank project is a large prospective
cohort study of over 500,000 individuals from across the United Kingdom, aged
between 40–69 at recruitment66. Genotyping was performed using a custom-made
Affimetrix chip, UK BiLEVE Axiom67 in the first 50,000 participants, and with
Affimetrix UK Biobank Axiom array in the remaining participants68, 95% of the
signals are on both chips. Imputation was performed by Wellcome Trust Centre for
Human Genetics using the Haplotype Reference Consortium (HRC) and the
UK10K haplotype resources11. This yields a total of 96 million imputed variants,
however only 40 million variants imputed using the HRC reference set were used in
this study due to quality issues with the remaining variants.
The population from UK Biobank consisted of 18,417 cases and 390,150
controls, all individuals of European ancestry. Gallstone disease was ascertained
based on self-reported (self-reported non-cancer illness, Data-Field 20002) and
ICD diagnoses obtained from primary or secondary diagnoses codes a participant
has had recorded across all their episodes in hospital. Diagnoses are coded
according to ICD-9 code 574 or ICD-10 code K80. The UKB Resource was
accessed under Application Number ‘24711’.
Association testing and meta-analysis. We used logistic regression to test for
association between variants and disease, assuming a multiplicative model, treating
disease status as the response and expected genotype counts as covariates. For the
Icelandic cohort, the association testing was done using software developed at
deCODE genetics7. The threshold for genome-wide significance was corrected for
multiple testing using a class-specific Bonferroni procedure based on predicted
functional impact of classes of variants12. This yielded significance thresholds of
2.0 × 10–7 for high-impact variants (including stop-gained, frameshift, splice
acceptor or donor, N= 11,465), 3.9 × 10–8 for moderate-impact variants (including
missense, splice-region variants and in-frame indels, N= 197,583), 3.6 × 10–9 for
low-impact variants (including upstream and downstream variants, N= 2,971,445)
and 5.9 × 10–10 for lowest-impact variants (including intron and intergenic var-
iants, N= 39,726,619). We have previously demonstrated that the variant anno-
tation based multiple testing method provides greater power to detect associations
than Bonferroni correction where all variants are treated equally, while maintaining
an overall family-wise error rate of 0.05. All variants except loss-of-function var-
iants (including stop-gained, frameshift, splice acceptor or donor) have p-value
thresholds stricter than the common threshold of 5.0 × 10–8, while loss-of-function
variants were given a threshold of 2.0 × 10–7 due to their higher prior probability of
representing true positive signals. In total, 42,907,111 variants were tested in the
meta-analysis. Variants in the UK Biobank imputation dataset have been mapped
to NCBI Build38 positions and subsequently matched to the variants in the Ice-
landic dataset based on allele variation. Results from UK and Iceland were com-
bined using a Mantel-Haenszel model69 in which the groups were allowed to have
different population frequencies for alleles and genotypes but were assumed to have
a common OR. We tested for heterogeneity by comparing the null hypothesis of
the effect being the same in all populations to the alternative hypothesis of each
population having a different effect using a likelihood ratio test. I2 describes the
proportion of total variation in study estimates due to heterogeneity.
Sibling recurrence risk. Sibling recurrence risk ratios (λS[i]) for the risk alleles of
the identified signals associated with gallstone disease in the present meta-analysis.
We estimated the risk ratio among siblings (λS) of Icelandic patients with
gallstone disease (N= 2628) by cross-matching with a genealogy database that
covers the entire Icelandic nation. Risk ratio among siblings (λS) was estimated
at 1.81 [1.71, 1.91] (P < 0.0001), using the approach suggested by Edvardsson
et al.70. Also, we calculated the proportion of sibling recurrence risk of gallstone
disease explained by the signals identified in the present study, which is given by
log(λS[i])/log(λS)71.
Population attributable fraction. Population attributable fraction is defined as the
fraction of cases that would be eliminated from the population if the risks of all
individuals carrying the risk variant could be contained, e.g., through a treatment,
to be the same as non-carriers of the at-risk variant(s). It can be calculated for a
variant using the following formula:
PAF= 1 – (1/W) where W= (1 − p)2+ 2p(1 − p)RR+ p2RR2
Here ‘p’ denotes the at-risk allele frequency and RR is the relative risk of for a
disease. Relative risks are estimated by odds ratios under the assumption of the
multiplicative model. Accordingly, the RR for carrying two risk variants is RR2.
Gene set enrichment analysis. Gene set enrichment analysis was conducted using
the online ToppGene tool41.
Binomial test for excess of cholesterol variants. Excess of gallstone
associated variants among reported HDL cholesterol, LDL cholesterol and total
cholesterol variants was tested using a binomial model, as follows: Since 170
variants were tested, a Bonferroni adjusted significance level of 0.05/170= 2.9 ×
10–4 was used. Thus, under the null hypothesis of no association with gallstone
disease, the probability of getting a significant association is 2.9 × 10–4 for
each variant, since the P-values for association with gallstone disease have a
Uniform[0,1] distribution under the null. Therefore, the number of significant
associations with gallstone disease in each group has a Binomial (N, P) dis-
tribution, where N is the number of tested variants in the group and P= 2.9 ×
10–4, and this can be used as the basis for a binomial test. For example, for
the HDL cholesterol variants, eight out of 83 variants associate with gallstone
disease, and the P-value for the binomial test of excess of HDL variants is
therefore Prob(X ≥ 8)= 2.2 × 10–18, where X has a Binomial(83, 2.9 × 10–4)
distribution.
URLs. For Online Mendelian Inheritance in Man (OMIM), see https://www.omim.
org/. For GWAS catalog, see https://www.ebi.ac.uk/gwas/. For GTEx Portal, see
https://www.gtexportal.org/.
Code availability. We used publicly available software (URLs listed below) in
conjunction with the above described algorithms in the sequencing processing
pipeline (Whole-genome sequencing, Association testing, RNA-seq mapping and
analysis): for BWA 0.7.10 mem, https://github.com/lh3/bwa; for
GenomeAnalysisTKLite 2.3.9, https://github.com/broadgsa/gatk/; for
Picard tools 1.117, https://broadinstitute.github.io/picard/; for
SAMtools 1.3, http://samtools.github.io/; for Bedtools v2.25.0-76-g5e7c696z,
https://github.com/arq5x/bedtools2/; for Variant Effect Predictor, https://github.
com/Ensembl/ensembl-vep; for BOLT-LMM, https://data.broadinstitute.org/
alkesgroup/BOLT-LMM/downloads/.
Data availability
Sequence variants passing GATK filters have been deposited in the European
Variation Archive, accession number PRJEB15197.
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